These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31578141)

  • 1. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
    Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
    BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
    Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
    Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison and validation of different risk models for papillary renal cell carcinoma.
    Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
    Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
    Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.
    Rosenkrantz AB; Sekhar A; Genega EM; Melamed J; Babb JS; Patel AD; Lo A; Najarian RM; Ahmed M; Pedrosa I
    Eur Radiol; 2013 Feb; 23(2):579-87. PubMed ID: 22903703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
    Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
    BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
    Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
    Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.
    Abel EJ; Masterson TA; Karam JA; Master VA; Margulis V; Hutchinson R; Lorentz CA; Bloom E; Bauman TM; Wood CG; Blute ML
    J Urol; 2017 Oct; 198(4):810-816. PubMed ID: 28411071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.
    Zucchi A; Novara G; Costantini E; Antonelli A; Carini M; Carmignani G; Cosciani Cunico S; Fontana D; Longo N; Martignoni G; Minervini A; Mirone V; Porena M; Roscigno M; Schiavina R; Simeone C; Simonato A; Siracusano S; Terrone C; Ficarra V
    BJU Int; 2012 Apr; 109(8):1140-6. PubMed ID: 21871053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
    Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
    Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
    Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is imagery distinctive in papillary renal cell carcinoma subtypes?
    Karray O; Ayed H; Saadi A; Zaghbib S; Henchir S; Cherif A; Ben Miled A; Chakroun M; Bouzouita A; Derouiche A; Ben Slama R; Chebil M
    Tunis Med; 2020 Feb; 98(2):131-137. PubMed ID: 32395802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes.
    Haddad MM; Schmit GD; Kurup AN; Schmitz JJ; Boorjian SA; Geske J; Thompson RH; Callstrom MR; Atwell TD
    J Vasc Interv Radiol; 2018 Aug; 29(8):1122-1126. PubMed ID: 29887184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
    Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
    Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy.
    Cindolo L; Chiodini P; Gallo C; Ficarra V; Schips L; Tostain J; de La Taille A; Artibani W; Patard JJ
    Cancer; 2008 Jul; 113(1):65-71. PubMed ID: 18473356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
    Buti S; Puligandla M; Bersanelli M; DiPaola RS; Manola J; Taguchi S; Haas NB
    Ann Oncol; 2017 Nov; 28(11):2747-2753. PubMed ID: 28945839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma.
    Huang J; Dahl DM; Dong L; Liu Q; Cornejo K; Wang Q; Wu S; Feldman AS; Huang Y; Xue W; Wu CL
    Biomed Res Int; 2015; 2015():891045. PubMed ID: 26448948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.